{"title":"转移性肝癌治疗的新模式:病例报告","authors":"E. Melo","doi":"10.33552/ajgh.2021.02.000550","DOIUrl":null,"url":null,"abstract":"of The results of the phase III study, IMbrave 150, which compared atezolizumab plus bevacizumab versus sorafenib, represented an important advance in the first-line treatment. We report a clinical case of a 78-year-old patient with metastatic hepatocarcinoma, who underwent first-line treatment with the combination of atezolizumab and bevacizumab. After 3 treatment cycles, there was a complete response in the lung and a partial response in the liver, opening the discussion about the possibility of considering at some point the local treatment of the liver in the face of tumor downstaging.","PeriodicalId":72038,"journal":{"name":"Academic journal of gastroenterology & hepatology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New Paradigms in the Treatment of Metastatic Hepatocarcinoma: Case Report\",\"authors\":\"E. Melo\",\"doi\":\"10.33552/ajgh.2021.02.000550\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"of The results of the phase III study, IMbrave 150, which compared atezolizumab plus bevacizumab versus sorafenib, represented an important advance in the first-line treatment. We report a clinical case of a 78-year-old patient with metastatic hepatocarcinoma, who underwent first-line treatment with the combination of atezolizumab and bevacizumab. After 3 treatment cycles, there was a complete response in the lung and a partial response in the liver, opening the discussion about the possibility of considering at some point the local treatment of the liver in the face of tumor downstaging.\",\"PeriodicalId\":72038,\"journal\":{\"name\":\"Academic journal of gastroenterology & hepatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Academic journal of gastroenterology & hepatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33552/ajgh.2021.02.000550\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Academic journal of gastroenterology & hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33552/ajgh.2021.02.000550","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
New Paradigms in the Treatment of Metastatic Hepatocarcinoma: Case Report
of The results of the phase III study, IMbrave 150, which compared atezolizumab plus bevacizumab versus sorafenib, represented an important advance in the first-line treatment. We report a clinical case of a 78-year-old patient with metastatic hepatocarcinoma, who underwent first-line treatment with the combination of atezolizumab and bevacizumab. After 3 treatment cycles, there was a complete response in the lung and a partial response in the liver, opening the discussion about the possibility of considering at some point the local treatment of the liver in the face of tumor downstaging.